Clinical significance of type 2 iodothyronine deiodinase polymorphism

References

• Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev. 2010;31:139–170.
   PubMed Web of Science ®Google Scholar
• Bianco AC, Salvatore D, Gereben B, et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23:38–89.
   PubMed Web of Science ®Google Scholar
• Visser WE, Friesema EC, Visser TJ. Minireview: thyroid hormone transporters: the knowns and the unknowns. Mol Endocrinol. 2011;25:1–14.
   PubMed Web of Science ®Google Scholar
• Kinne A, Schülein R, Krause G. Primary and secondary thyroid hormone transporters. Thyroid Res. 2011 Aug;3(4 Suppl 1):S7.
   Google Scholar
• Larsen PR. Thyroid-pituitary interaction: feedback regulation of thyrotropin secretion by thyroid hormones. N Engl J Med. 1982;306:23–32.
   PubMed Web of Science ®Google Scholar
• Christoffolete MA, Ribeiro R, Singru P, et al. Atypical expression of type 2 iodothyronine deiodinase in thyrotrophs explains the thyroxine-mediated pituitary thyrotropin feedback mechanism. Endocrinology. 2006;147:1735–1743.
   PubMed Web of Science ®Google Scholar
• Fekete C, Freitas BC, Zeöld A, et al. Expression patterns of WSB-1 and USP-33 underlie cellspecific posttranslational control of type 2 deiodinase in the rat brain. Endocrinology. 2007;148:4865–4874.
   PubMed Web of Science ®Google Scholar
• Schneider MJ, Fiering SN, Thai B, et al. Targeted disruption of the type 1 selenodeiodinase gene (Dio1) results in marked changes in thyroid hormone economy in mice. Endocrinology. 2006;147:580–589.
   PubMed Web of Science ®Google Scholar
• Baqui M, Botero D, Gereben B, et al. Human type 3 iodothyronine selenodeiodinase is located in the plasma membrane and undergoes rapid internalization to endosomes. J Biol Chem. 2003;278:1206–1211.
   PubMed Web of Science ®Google Scholar
• Zavacki AM, Ying H, Christoffolete MA, et al. Type 1 iodothyronine deiodinase is a sensitive marker of peripheral thyroid status in the mouse. Endocrinology. 2005;146:1568–1575.
   PubMed Web of Science ®Google Scholar
• Gereben B, Goncalves C, Harney JW, et al. Selective proteolysis of human type 2 deiodinase: a novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation. Mol Endocrinol. 2000;14:1697–1708.
   PubMedGoogle Scholar
• Dentice M, Salvatore D. Local impact of thyroid hormone inactivation. J Endocrinol. 2011.
   PubMedGoogle Scholar
• Gereben B, Zavacki AM, Ribich S, et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev. 2008;29:898–938.
   PubMed Web of Science ®Google Scholar
• Grarup N, Andersen MK, Andreasen CH, et al. Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 Danish white subjects. J Clin Endocrinol Metab. 2007;92(1):363–366.
   PubMed Web of Science ®Google Scholar
• Cooper DS. Clinical practice subclinical hypothyroidism. N Engl J Med. 2001;345:260–265.
   PubMed Web of Science ®Google Scholar
• Toft AD. Clinical practice subclinical hyperthyroidism. N Engl J Med. 2001;345:512–516.
   PubMed Web of Science ®Google Scholar
• Jackson IM. The thyroid axis and depression. Thyroid. 1998;8:951–956.
   PubMed Web of Science ®Google Scholar
• Samuels MH. Subclinical thyroid disease in the elderly. Thyroid. 1998;8:803–813.
   PubMed Web of Science ®Google Scholar
• Pucci E, Chiovato L, Pinchera A. Thyroid and lipid metabolism. Int J Obes Relat Metab Disord. 2000;24:S109–S112.
   PubMed Web of Science ®Google Scholar
• Hak AE, Pols HA, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann Intern Med. 2000;132:270–278.
   PubMed Web of Science ®Google Scholar
• Peeters RP, van Toor H, Klootwijk W, et al. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab. 2003 Jun;88(6):2880–2888.
   PubMed Web of Science ®Google Scholar
• Wouters HJCM, Hcm VL, van der Klauw MM, et al. No effect of the Thr92Ala polymorphism of deiodinase-2 on thyroid hormone parameters, health-related quality of life, and cognitive functioning in a large population-based cohort study. Thyroid. 2017;27:147–155.
   PubMed Web of Science ®Google Scholar
• Peeters RP, van Den Beld AW, Attalki H, et al. A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. Am J Physiol Endocrinol Metab. 2005 Jul;289(1):E75–81. Epub 2005 Feb 22.
   PubMed Web of Science ®Google Scholar
• Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94:1623–1629.
   PubMed Web of Science ®Google Scholar
• Gullo D, Latina A, Frasca F, et al. Levothyroxine monotherapy cannot guarantee euthiroidism in all athyreotic patients. Plos one. 2011;6(8).
   PubMed Web of Science ®Google Scholar
• Ito M, Miyauchi A, Morita S, et al. TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy. Eur J Endocrinol. 2012;167:373–378.
   PubMed Web of Science ®Google Scholar
• Jonklaas J, Davidson B, Bhagat S, et al. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA. 2008;299(7):769–777.
   PubMed Web of Science ®Google Scholar
• Torlontano M, Durante C, Torrente I, et al. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts l-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. J Clin Endocrinol Metab. 2008;93(3):910–913.
   PubMed Web of Science ®Google Scholar
• Heemstra KA, Hoftijzer HC, van der Deure WM, et al. Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis. Clin Endocrinol (Oxf). 2009;71(2):279–283.
   PubMed Web of Science ®Google Scholar
• Al-Azzam SI, Alkhateeb AM, Al-Azzeh O, et al. The role of type II deiodinase polymorphisms in clinical management of hypothyroid patients treated with levothyroxine.Exp. Clin Endocrinol Diabetes. 2013 May;121(5):300–305.
   PubMed Web of Science ®Google Scholar
• Castagna MG, Dentice M, Cantara S, et al. DIO2 Thr92Ala reduces deiodinase-2 activity and serum-T3 levels in thyroid-deficient patients. J Clin Endocrinol Metab. 2017;102(1623–1630).
   PubMedGoogle Scholar
• Hoftijzer HC, Heemstra KA, Visser TJ, et al. The type 2 deiodinase ORFa-Gly3Asp polymorphism (rs12885300) influences the set point of the hypothalamus-pituitary-thyroid axis in patients treated for differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2011 Sep;96(9):E1527–33.
   PubMed Web of Science ®Google Scholar
• Guo TW, Zhang FC, Yang MS, et al. Positive association of the DIO2 (deiodinase type 2) gene with mental retardation in the iodine-deficient areas of China.J. Med Genet. 2004 Aug;41(8):585–590.
   PubMed Web of Science ®Google Scholar
• He B, Li J, Wang G, et al. Association of genetic polymorphisms in the type II deiodinase gene with bipolar disorder in a subset of Chinese population. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31;33(6):986–990.
   PubMed Web of Science ®Google Scholar
• Gałecka E, Talarowska M, Orzechowska A, et al. Association of the DIO2 gene single nucleotide polymorphisms with recurrent depressive disorder. Acta Biochim Pol. 2015;62(2):297–302.
   PubMed Web of Science ®Google Scholar
• Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psycological well-being and response to combination thyroxine plus triidothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94(5):1623–1629.
   PubMed Web of Science ®Google Scholar
• Carle A, Faber J, Steffensen R, et al. Hypothyroid patients encoding combined MCT10 and DIO2 gene polymorphisms may prefer L-T3 + LT4 combination treatment – data using a blind, randomized clinical study. Eur Thyroid J. 2017;6:143–151.
   PubMed Web of Science ®Google Scholar
• Appelhof BC, Peeters RP, Wiersinga WM, et al. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3’-triiodothyronine therapy. J Clin Endocrinol Metab. 2005;90:6296–6299.
   PubMed Web of Science ®Google Scholar
• Medici M, Chaker L, Peeters RP. A step forward in 542 understanding therelevance of genetic variation in type 2 deiodinase. J Clin Endocrinol Metab. 2017 May 1;102(5):1775–1778.
   PubMed Web of Science ®Google Scholar
• Canani LH, Capp C, Dora JM, et al. The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2005;90(6):3472–3478.
   PubMed Web of Science ®Google Scholar
• Mentuccia D, Proietti-Pannunzi L, Tanner K, et al. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor. Diabetes. 2002 Mar;51(3):880–883.
   PubMed Web of Science ®Google Scholar
• Dora JM, Machado WE, Rheinheimer J, et al. Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: case-control study and metaanalysis. Eur J Endocrinol. 2010;163(3):427–434.
   PubMed Web of Science ®Google Scholar
• Grarup N, Andersen MK, Andreasen CH, et al. Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 Danish white subjects. J Clin Endocrinol Metab. 2007;92(1):363–366.
   PubMed Web of Science ®Google Scholar
• Mentuccia D, Thomas MJ, Coppotelli G, et al. The Thr92Ala deiodinase type 2 (DIO2) variant is not associated with type 2 diabetes or indices of insulin resistance in the Old Order of Amish. Thyroid. 2005;15(11):1223–1227.
   PubMed Web of Science ®Google Scholar
• Maia AL, Dupuis J, Manning A, et al. The type 2 deiodinase (DIO2) A/G polymorphism is not associated with glycemic traits, The Framingham Heart Study. Thyroid. 2007;17(3):199–202.
   PubMed Web of Science ®Google Scholar
• Zhang X, Sun J, Han W, et al. The type 2 deiodinase Thr92Ala polymorphism is associated with worse glycemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Diabetes Res. 2016;2016: 5928726. Epub 2016 Sep 29. Review.
   PubMedGoogle Scholar
• Estivalet AA, Leiria LB, Dora JM, et al. D2 Thr92Ala and PPARγ2 Pro12Ala polymorphisms interact in the modulation of insulin resistance in type 2 diabetic patients. Obesity (Silver Spring). 2011 Apr;19(4):825–832.
   PubMed Web of Science ®Google Scholar
• Leiria LB, Dora JM, Wajner SM, et al. The rs225017 polymorphism in the 3’UTR of the human DIO2 gene is associated with increased insulin resistance. PLoS One. 2014 Aug 8;9(8):e103960. . Ecollection 2014.
   PubMed Web of Science ®Google Scholar
• He B, Li J, Wang G, et al. Association of genetic polymorphisms in the type II deiodinase gene with bipolar disorder in a subset of Chinese population. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(6):986–990.
   PubMed Web of Science ®Google Scholar
• Gałecka E, Talarowska M, Orzechowska A, et al. Association of the DIO2 gene single nucleotide polymorphisms with recurrent depressive disorder. Acta Biochim Pol. 2015;62(2):297–302.
   PubMed Web of Science ®Google Scholar
• Gumieniak O, Perlstein TS, Williams JS, et al. Ala92 type 2 deiodinase allele increases risk for the development of hypertension. Hypertension. 2007;49(3):461–466.
   PubMed Web of Science ®Google Scholar
• Loughlin J. Genetic contribution to osteoarthritis development, Current State of Evidence. Curr Opin Rheumatol. 2015;27(3):284–288.
   PubMed Web of Science ®Google Scholar
• Meulenbelt I, Min JL, Bos S, et al. Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis. Hum Mol Genet. 2008;17(12):1867–1875.
   PubMed Web of Science ®Google Scholar
• Grineva E, Babenko A, Vahrameeva N, et al. Type 2 deiodinase Thr92Ala polymorphism impact on clinical course and myocardial remodeling in patients with Graves’ disease. Cell Cycle. 2009;8:2565–2569.
   PubMed Web of Science ®Google Scholar
• Heemstra KA, Hoftijzer H, van der Deure WM, et al. The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density. J Bone Miner Res. 2010;25:1385–1391.
   PubMed Web of Science ®Google Scholar
• Barca-Mayo O, Liao XH, DiCosmo C, et al. Role of type 2 deiodinase in response to acute lung injury (ALI) in mice. Proc Natl Acad Sci U S A. 2011;108:E1321–E1329.
   PubMed Web of Science ®Google Scholar
• Ma SF, Xie L, Pino-Yanes M, et al. Type 2 deiodinase and host responses of sepsis and acute lung injury. Am J Respir Cell Mol Biol. 2011;45:1203–1211.
   PubMed Web of Science ®Google Scholar